BRPI0718520A2 - Composto, métodos para a modulação do receptor de adenosina a1 e para o tratamento de condições mediadas pelo receptor de adenosina a1 em mamíferos, composição farmacêutica, e, usos de uma composição e de um composto - Google Patents

Composto, métodos para a modulação do receptor de adenosina a1 e para o tratamento de condições mediadas pelo receptor de adenosina a1 em mamíferos, composição farmacêutica, e, usos de uma composição e de um composto Download PDF

Info

Publication number
BRPI0718520A2
BRPI0718520A2 BRPI0718520-0A BRPI0718520A BRPI0718520A2 BR PI0718520 A2 BRPI0718520 A2 BR PI0718520A2 BR PI0718520 A BRPI0718520 A BR PI0718520A BR PI0718520 A2 BRPI0718520 A2 BR PI0718520A2
Authority
BR
Brazil
Prior art keywords
chlorophenyl
amino
methyl
methanone
thiophen
Prior art date
Application number
BRPI0718520-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Pier Giovanni Baraldi
Allan R Moorman
Romeo Romagnoli
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/938,465 external-priority patent/US7855209B2/en
Priority claimed from US11/938,514 external-priority patent/US7897596B2/en
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of BRPI0718520A2 publication Critical patent/BRPI0718520A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/113Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0718520-0A 2006-11-13 2007-11-13 Composto, métodos para a modulação do receptor de adenosina a1 e para o tratamento de condições mediadas pelo receptor de adenosina a1 em mamíferos, composição farmacêutica, e, usos de uma composição e de um composto BRPI0718520A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US85850506P 2006-11-13 2006-11-13
US60/858,505 2006-11-13
US11/938,465 US7855209B2 (en) 2006-11-13 2007-11-12 Allosteric modulators of the A1 adenosine receptor
US11/938,465 2007-11-12
US11/938,514 US7897596B2 (en) 2006-11-13 2007-11-12 Allosteric modulators of the A1 adenosine receptor
US11/938,514 2007-11-12
PCT/US2007/084490 WO2008063984A2 (en) 2006-11-13 2007-11-13 Allosteric modulators of the a1 adenosine receptor

Publications (1)

Publication Number Publication Date
BRPI0718520A2 true BRPI0718520A2 (pt) 2013-11-19

Family

ID=39430473

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718520-0A BRPI0718520A2 (pt) 2006-11-13 2007-11-13 Composto, métodos para a modulação do receptor de adenosina a1 e para o tratamento de condições mediadas pelo receptor de adenosina a1 em mamíferos, composição farmacêutica, e, usos de uma composição e de um composto

Country Status (9)

Country Link
EP (1) EP2081575A4 (enExample)
JP (1) JP2010509402A (enExample)
KR (1) KR20090112627A (enExample)
AU (1) AU2007323888A1 (enExample)
BR (1) BRPI0718520A2 (enExample)
CA (1) CA2669447A1 (enExample)
IL (1) IL198402A0 (enExample)
MX (1) MX2009004763A (enExample)
WO (1) WO2008063984A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739588B (zh) * 2014-01-04 2015-07-01 新发药业有限公司 一种2-氨基噻吩衍生物的简便合成方法
US10434099B2 (en) 2016-09-22 2019-10-08 The National Institute for Biotechnology in the Negev Ltd. Methods for treating central nervous system disorders using VDAC inhibitors
ES2815539T3 (es) * 2015-09-14 2021-03-30 Nat Inst Biotechnology Negev Ltd Nuevos derivados de piperazina y piperidina, síntesis y uso de los mismos en la inhibición de la oligomerización de VDAC, la apoptosis y la disfunción mitocondrial
US10787423B2 (en) 2015-09-14 2020-09-29 The National Institute For Biotechnolgy In The Negev Ltd. Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction
US11220505B2 (en) * 2017-03-21 2022-01-11 Temple University-Of The Commonwealth System Of Higher Education 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
JP7365237B2 (ja) * 2017-03-21 2023-10-19 テンプル・ユニバーシティ-オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション シグマ-2受容体の新規調節物質およびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332732A (en) * 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
EP0595150B1 (de) * 1992-10-29 1996-07-31 Hoechst Aktiengesellschaft Verfahren zur Herstellung von aromatischen Brommethyl-Verbindungen
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor

Also Published As

Publication number Publication date
EP2081575A2 (en) 2009-07-29
CA2669447A1 (en) 2008-05-29
IL198402A0 (en) 2010-02-17
KR20090112627A (ko) 2009-10-28
WO2008063984A3 (en) 2008-08-14
AU2007323888A1 (en) 2008-05-29
MX2009004763A (es) 2009-05-21
EP2081575A4 (en) 2010-01-06
JP2010509402A (ja) 2010-03-25
WO2008063984A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
CN102153562B (zh) 螺-吲哚酮化合物及其作为治疗剂的用途
CA2651732C (en) Intracellular kinase inhibitors
US20150141424A1 (en) IRE-1alpha INHIBITORS
WO2008046083A2 (en) Use of oxindole compounds as therapeutic agents
BRPI0710527B1 (pt) compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
JP2004520273A (ja) Parpの阻害剤として用いるためのチエノ[2,3−c]イソキノリン
HUP0104280A2 (hu) Dopamin D3 receptorok modulátoraiként felhasználható tetrahidrobenzazepin-származékok, eljárás az előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények
ES2594409T9 (es) Derivados de heteroarilo como moduladores del nAChR alfa7
JP2010505834A (ja) 非ヌクレオシド系逆転写酵素阻害剤
BR112015030399B1 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
US12291523B2 (en) LXR modulators with bicyclic core moiety
KR20090114439A (ko) 아실구아니딘 유도체
BRPI0718520A2 (pt) Composto, métodos para a modulação do receptor de adenosina a1 e para o tratamento de condições mediadas pelo receptor de adenosina a1 em mamíferos, composição farmacêutica, e, usos de uma composição e de um composto
ES2250345T3 (es) Derivados sustituidos de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico.
ES2379734T3 (es) Derivado de pirrol o sal del mismo
ES2724111T3 (es) Derivados de 2-aril-4-hidroxi-1,3-tiazol útiles como inhibidores de TRPM8 en el tratamiento de neuralgia, dolor, EPOC y asma
US7855209B2 (en) Allosteric modulators of the A1 adenosine receptor
US7897596B2 (en) Allosteric modulators of the A1 adenosine receptor
US20120108636A1 (en) Allosteric Enhancers of th A1 Adenosine Receptor
ES2211738T3 (es) Derivados de diazabiciclooctano y sus usos terapeuticos.
Nakao et al. Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 1
WO2015101265A1 (zh) 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
CN101534828A (zh) A1腺苷受体的别构调节物
JP2006527258A (ja) 5ht1b受容体のアンタゴニストとしてのテトラヒドロキノリン類
RU2780247C1 (ru) ПРИМЕНЕНИЕ ТРИЦИКЛИЧЕСКОГО СЕРУСОДЕРЖАЩЕГО ПРОИЗВОДНОГО 1,2-ДИГИДРОХИНОЛИНА ДЛЯ ИНГИБИРОВАНИЯ РЕПЛИКАЦИИ БЕТА-КОРОНАВИРУСОВ, ВКЛЮЧАЯ SARS-CoV-2

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.